Ayala Pharmaceuticals has two clinical-stage cancer drugs licensed from Bristol Myers Squibb. Now it has $55 million to take those drugs further than the pharmaceutical giant did. On Thursday evening, Ayala priced its IPO, which consisted of 3.7 million shares sold for $15 each. That price was the midpoint of the targeted $14 to $16 … Continue reading “Ayala’s IPO Raises $55M to Test Two Former Bristol Myers Cancer Drugs”
Trovagene Rebrands as Cardiff Oncology, Promotes Longtime Exec to CEO
Trovagene (NASDAQ: [[ticker:TROV]]), which started out as a diagnostics company, has renamed itself Cardiff Oncology to better reflect its focus on the cancer drug it is advancing in three clinical trials. In 2017 the San Diego area-based biotech made the first step in its transformation into a drug development-focused organization, licensing rights to an investigational … Continue reading “Trovagene Rebrands as Cardiff Oncology, Promotes Longtime Exec to CEO”
Gemini Therapeutics Names Ex-Achillion Exec Marc Uknis Chief Medical Officer
Gemini Therapeutics has appointed Marc Uknis to serve as its chief medical officer. Uknis was most recently a vice president at Achillion, which was acquired by Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]) last year. His experience also includes positions at ViroPharma and CSL Behring. Cambridge, MA-based Gemini launched in 2017 to develop treatments for age-related macular degeneration. … Continue reading “Gemini Therapeutics Names Ex-Achillion Exec Marc Uknis Chief Medical Officer”
Akcea Adds Vertex’s Carla Poulson as Chief Human Resources Officer
Akcea Therapeutics (NASDAQ: [[ticker:AKCA]]) appointed Carla Poulson as chief human resources officer. Poulson was most recently vice president, senior human resources business partner at Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]). Her prior experience includes roles at grocery retail group Ahold, Pepsi Bottling Group, and ExxonMobil (NYSE: [[ticker:XOM]]). Boston-based Akcea, a spinoff of Carlsbad, CA-based Ionis Pharmaceuticals (NASDAQ: … Continue reading “Akcea Adds Vertex’s Carla Poulson as Chief Human Resources Officer”
FogPharma Appoints Tony Gibney as Chief Financial, Business Officer
FogPharma on Thursday named Tony Gibney to the roles of chief financial officer and chief business officer. Gibney, who was an investment banker before transitioning into biotech, was most recently CBO at Achillion Pharmaceuticals, where he led the process that concluded in Achillion’s sale to Alexion, a deal that closed in January. Previously he held … Continue reading “FogPharma Appoints Tony Gibney as Chief Financial, Business Officer”
PTC Therapeutics to Acquire Censa Pharma for Mid-Stage Rare Disease Drug
PTC Therapeutics has reached an agreement to acquire Censa Pharmaceuticals and its lead asset, an experimental metabolic disorder therapy that is now being prepared for a pivotal study. The deal, announced after the market close Wednesday, will bring South Plainfield, NJ-based PTC (NASDAQ: [[ticker:PTCT]]) another compound for its pipeline of rare disease drugs. Want more … Continue reading “PTC Therapeutics to Acquire Censa Pharma for Mid-Stage Rare Disease Drug”
Novartis Drug Wins FDA Approval for Lung Cancers With Specific Mutation
As cancer research reveals the genetic basis of the disease, pharmaceutical companies are pursuing targeted therapies that address certain groups of patients. One such drug from Novartis won FDA approval Wednesday, making it the first therapy cleared by the agency to treat patients whose non-small cell lung cancer (NSCLC) carries a certain genetic mutation. The … Continue reading “Novartis Drug Wins FDA Approval for Lung Cancers With Specific Mutation”
AstraZeneca Diabetes Drug Gets FDA OK for Reducing Heart Health Risks
An AstraZeneca diabetes drug that brought in more than $1.5 billion in sales last year has won an FDA nod expanding its use to adults with systolic heart failure, a condition in which the heart struggles to pump with enough force to push enough blood into circulation. The drug, the once-daily pill dapagliflozin (Farxiga), was … Continue reading “AstraZeneca Diabetes Drug Gets FDA OK for Reducing Heart Health Risks”
Kezar Life Sciences Taps Noreen Roth Henig as Chief Medical Officer
Kezar Life Sciences (NASDAQ: [[ticker:KZR]]) has appointed Noreen Roth Henig to serve as its chief medical officer, the same role she held most recently at Breath Therapeutics. Breath was acquired by Zambon last year for €140 million up front. Henig’s experience also includes roles at ProQR Therapeutics and Gilead Sciences (NASDAQ: [[ticker:GILD]]). South San Francisco-based … Continue reading “Kezar Life Sciences Taps Noreen Roth Henig as Chief Medical Officer”
Ventus Launches With $60M to Shine Light on Innate Immune System Drugs
The innate immune system has become a hot area for drug development, and for good reason. As the body’s first line of defense, its function (or dysfunction) plays a role in many diseases. The problem, says Ventus Therapeutics CEO Marcelo Bigal, is that drug developers have been working in the dark. Scientists don’t know the … Continue reading “Ventus Launches With $60M to Shine Light on Innate Immune System Drugs”
Encouraging Signals for New Cancer Cell Therapy Strategies
Chimeric antigen receptor T-cell therapies have shown remarkable efficacy in leukemia and lymphoma patients who relapsed or were refractory to several prior treatments, but many challenges remain in the cancer cell therapy field. Strategies that may improve upon first-generation therapies were presented during the American Association for Cancer Research virtual meeting with encouraging early activity, … Continue reading “Encouraging Signals for New Cancer Cell Therapy Strategies”
Kura Narrows Pipeline After Strategic Review Prompted by COVID-19
Kura Oncology is discontinuing development of one of its three clinical-stage cancer drug candidates amid pandemic-related impacts to its clinical trial plans. The decision to end work on the drug, KO-947, comes after San Diego-based Kura (NASDAQ: [[ticker:KURA]]) was successful in lifting a partial clinical hold placed on a Phase 1 trial of the drug … Continue reading “Kura Narrows Pipeline After Strategic Review Prompted by COVID-19”
Alexion Pharma Boosts Blood Drug Lineup With $1.4B Deal for Portola
Alexion Pharmaceuticals has agreed to buy Portola Pharmaceuticals in a $1.4 billion deal that brings it a first-in-class therapy for treating life-threatening bleeding. According to financial terms announced Tuesday, Boston-based Alexion (NASDAQ: [[ticker:ALXN]]) will pay $18 for each outstanding share of Portola (NASDAQ: [[ticker:PTLA]]). That price is a a nearly 132 percent premium to Monday’s … Continue reading “Alexion Pharma Boosts Blood Drug Lineup With $1.4B Deal for Portola”
COVID-19 and Fungal Superinfections: The Deadly, Perfect Storm
Virtually unknown just a few months ago, the COVID-19 pandemic has already resulted in over 239,000 deaths worldwide—including over 67,000 in the United States alone. Now, emerging reports suggest that as many as one third of patients with severe COVID-19 infection requiring intensive care may also be battling another life-threatening infection: invasive aspergillosis, a deadly … Continue reading “COVID-19 and Fungal Superinfections: The Deadly, Perfect Storm”
Arrowhead Pharma’s Chief Operating Officer Bruce Given Retires
Bruce Given, chief operating officer and head of R&D for Arrowhead Pharmaceuticals (NASDAQ: [[ticker:ARWR]]), has retired. Given’s responsibilities are being divided among the company’s chief medical officer, chief scientific officer, and chief commercial officer. Given, who joined Arrowhead in 2011, will serve as an advisor to the Pasadena, CA, company for at least one year. … Continue reading “Arrowhead Pharma’s Chief Operating Officer Bruce Given Retires”
Stemline Slated for Acquisition by Menarini in Deal Worth Up to $677M
Stemline Therapeutics, whose drug for a rare, aggressive type of acute leukemia was approved by the FDA about 18 months ago, has signed an acquisition deal with Italian biopharma Menarini Group. Stemline (NASDAQ: [[ticker:STML]]), a New York-based company, developed the first FDA-approved drug for blastic plasmacytoid dendritic cell neoplasm, or BPDCN. The drug, tagraxofusp (Elzonris) … Continue reading “Stemline Slated for Acquisition by Menarini in Deal Worth Up to $677M”
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
The genetic mutations that cause epilepsy don’t stop there. Praxis Precision Medicines CEO Marcio Souza says research also links these genes to other neurological conditions. The biotech startup is turning that research into new neuro drugs and it’s coming out of stealth to share details about its science and its pipeline, which already has two … Continue reading “Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs”
Pfizer Pays Valneva $130M for a Bite at a Lyme Disease Vaccine
If you’re looking for a Lyme disease vaccine, you can choose from among several—for your dog. A vaccine for humans hasn’t been available for years and few companies have tried to fill that void. Valneva has advanced its Lyme vaccine candidate to mid-stage clinical testing, and the company now has the help of drug giant … Continue reading “Pfizer Pays Valneva $130M for a Bite at a Lyme Disease Vaccine”
FDA Authorizes “Emergency” Use of Gilead’s Remdesivir for Severe COVID-19
Regulators on Friday afternoon granted emergency authorization for the Gilead Sciences drug remdesivir as a treatment for patients hospitalized with severe COVID-19 infections. The decision makes the antiviral drug, which is delivered via intravenous infusion, the second drug to receive authorization under the FDA’s emergency guidelines for use against the novel coronavirus. The first was … Continue reading “FDA Authorizes “Emergency” Use of Gilead’s Remdesivir for Severe COVID-19″
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
Lyra Therapeutics, a biotech company developing a new way to treat your persistently runny nose, has raised $56 million in its public markets debut. Late Thursday, Lyra offered 3.5 million shares priced at $16 apiece, which was the high end of its projected $14 to $16 price range. Those shares are expected to begin trading … Continue reading “Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses”
Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More
Remdesivir, the investigational Gilead Sciences antiviral drug, looks more likely than ever to become the first treatment authorized by the FDA to treat patients with COVID-19. National Institute of Allergy and Infectious Diseases (NIAID) head Anthony Fauci praised the drug after preliminary data released this week from a federally funded trial involving more than 1,000 … Continue reading “Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More”
Goldfinch Bio Adds Kyle Kuvalanka, Lori Rudolph-Owen to C-Suite
Goldfinch Bio has appointed Kyle Kuvalanka to serve as chief financial and chief operating officer. His experience includes positions at Syros Pharmaceuticals, Blueprint Medicines (NASDAQ: [[ticker:BPMC]]), and Takeda Pharmaceutical (NYSE: [[ticker:TAK]]). In other moves, Cambridge, MA-based Goldfinch promoted Lori Rudolph-Owen to chief development officer. She joined the company in 2018 as senior vice president of … Continue reading “Goldfinch Bio Adds Kyle Kuvalanka, Lori Rudolph-Owen to C-Suite”
Intellia Therapeutics Taps Semma’s Lebwohl as Chief Medical Officer
Intellia Therapeutics (NASDAQ: [[ticker:NTLA]]) has appointed David Lebwohl to serve as executive vice president and chief medical officer. He is joining the Cambridge, MA-based gene-editing therapies company from Semma Therapeutics, where he also held the chief medical officer position. Lebwohl’s prior experience includes positions at Novartis (NYSE: [[ticker:NVS]]) and Bristol Myers Squibb (NYSE: [[ticker:BMY]]). Intellia is … Continue reading “Intellia Therapeutics Taps Semma’s Lebwohl as Chief Medical Officer”
Podcast: How San Diego is Building a Biotech Ecosystem – Genomics & Precision Medicine Experts Weigh in
Miss the event or want to revisit the insightful content? Our new podcast packages the highlights from the recent Xcelerating Life Sciences San Diego: Biomedical Breakthroughs in Precision Medicine & Genomics forum. Listen today. Featuring expert panels on: Successful R&D models What it takes for commercialization Building a biotech ecosystem in San Diego Dozens of … Continue reading “Podcast: How San Diego is Building a Biotech Ecosystem – Genomics & Precision Medicine Experts Weigh in”
BridgeBio’s Pipeline Expansion Continues as Portfolio’s Milestones Approach
BridgeBio Pharma Inc. is poised to achieve its goal of rapidly bringing treatments for genetic diseases and genetically defined cancers to the market with two different products expected to be submitted to the US Food and Drug Administration before the end of 2021—just four years after the company’s first big funding round. Palo Alto, CA-based … Continue reading “BridgeBio’s Pipeline Expansion Continues as Portfolio’s Milestones Approach”
Adicet Aims to Advance CAR-T Therapies in Reverse Merger with resTORbio
Adicet Bio, a privately held preclinical biotech looking to move ahead its “off-the-shelf” CAR-T cell therapies, has struck a deal with struggling resTORbio to use its Nasdaq listing as a backdoor to the public markets. The companies on Wednesday announced an agreement to combine in a type of transaction sometimes referred to as a “reverse … Continue reading “Adicet Aims to Advance CAR-T Therapies in Reverse Merger with resTORbio”
Radius Health CEO Hoeiland Steps Down, Martin Named Successor
Radius Health (NASDAQ: [[ticker:RDUS]]) president and CEO Jesper Hoeiland has stepped down, the company announced Tuesday. In a statement, Hoeiland said that after nearly 25 years abroad, he and his wife decided to return to Denmark to be closer to family and friends. According to a securities filing, he will serve as a paid advisor … Continue reading “Radius Health CEO Hoeiland Steps Down, Martin Named Successor”
Forma Therapeutics Taps Ex-Seres Exec Cook as Chief Scientific Officer
Forma Therapeutics has appointed David Cook to serve as its senior vice president and chief scientific officer. Cook’s experience includes senior roles at Seres Therapeutics (NASDAQ: [[ticker:MCRB]]), the International AIDS Vaccine Initiative, Anza Therapeutics, and Cerus Corporation. Watertown, MA-based Forma develops drugs for rare blood diseases and cancers. The company’s most advanced program, olutasidenib, is … Continue reading “Forma Therapeutics Taps Ex-Seres Exec Cook as Chief Scientific Officer”
Supernus Makes a Parkinson’s Play With $300M Deal for US WorldMeds Drugs
Supernus Pharmaceuticals is expanding its central nervous system (CNS) drug lineup through a deal to acquire four US WorldMeds products with applications in Parkinson’s disease. The products, three of them already on the market and one in late-stage development, comprise the CNS portfolio of Louisville, KY-based US WorldMeds. According to terms of the deal, Supernus … Continue reading “Supernus Makes a Parkinson’s Play With $300M Deal for US WorldMeds Drugs”
Taysha Launches With $30M to Bring Gene Therapy to CNS Disorders
Some former executives and investors behind the second gene therapy to win FDA approval are teaming up again. Their new company, Taysha Gene Therapies, is launching with $30 million in the bank and a plan to bring its first central nervous system (CNS) disorder program into human testing later this year. Taysha is focusing on … Continue reading “Taysha Launches With $30M to Bring Gene Therapy to CNS Disorders”
AMAG Pharma Appoints Rainier’s Myers to Succeed CEO William Heiden
AMAG Pharmaceuticals (NASDAQ: [[ticker:AMAG]]) on Tuesday announced Scott Myers has been appointed its new CEO. Myers was most recently CEO of bladder cancer drug developer Rainier Therapeutics. Previously he served as CEO of Cascadian Therapeutics, which was acquired by Seattle Genetics (NASDAQ: [[ticker:SGEN]]) in 2018. He also spent time as CEO of medical device company … Continue reading “AMAG Pharma Appoints Rainier’s Myers to Succeed CEO William Heiden”
Aurinia Taps Cerecor’s Miller to Succeed Retiring Chief Financial Officer
Aurinia Pharmaceuticals (NASDAQ: [[ticker:AUPH]]) announced that Joe Miller would become its new chief financial officer, succeeding Dennis Bourgeault, who is retiring after more than 20 years as its CFO. Miller was most recently CFO and corporate secretary at Cerecor (NASDAQ: [[ticker:CERC]]). His prior experience includes roles at Sucampo Pharmaceuticals, which merged with Mallinckrodt (NYSE: [[ticker:MNK]]) in … Continue reading “Aurinia Taps Cerecor’s Miller to Succeed Retiring Chief Financial Officer”
At Rome Therapeutics, Kapeller Aims to Turn “Junk” Into New Drugs
A new biotech, Rome Therapeutics, launched Monday with $50 million and a plan to develop novel drugs based on new insights into repeats in the non-coding stretches of the human genome. Rome’s debut pulls back the curtain on what Rosana Kapeller, the company’s co-founder and CEO, has been up to since she left Nimbus Therapeutics … Continue reading “At Rome Therapeutics, Kapeller Aims to Turn “Junk” Into New Drugs”
Mirum Appoints Global Blood’s Radovich as Its Chief Operating Officer
Mirum Pharmaceuticals (NASDAQ: [[ticker:MIRM]]) has added Peter Radovich to its C-suite as its chief operating officer. Radovich was most recently executive vice president, operations for South San Francisco-based Global Blood Therapeutics (NASDAQ: [[ticker:GBT]]). Foster City, CA-based Mirum, which launched in 2018 after licensing its lead compound from Shire, is developing liver disease drugs. The biotech … Continue reading “Mirum Appoints Global Blood’s Radovich as Its Chief Operating Officer”
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
Many patients with Parkinson’s disease take a combination medication called levodopa/carbidopa to control their symptoms, but over time, experience “off” episodes in which the tremor, slowed movement, and difficulty walking that characterize the disorder occur. Now the FDA has approved a Neurocrine Biosciences (NASDAQ: [[ticker:NBIX]]) drug intended to be taken along with levodopa/carbidopa to extend … Continue reading “Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill”
Erasca Lands $200M Mega-Round to Move Cancer Programs to the Clinic
Serial biotech entrepreneur Jonathan Lim has raised a whopping $200 million to advance multiple candidates at his latest cancer drug development venture, Erasca, into human testing. Lim (pictured) sold his previous company, Ignyta, to Roche for $1.7 billion. On Monday Erasca—a portmanteau of “erase” and “cancer”—announced it had completed a Series B financing round jointly … Continue reading “Erasca Lands $200M Mega-Round to Move Cancer Programs to the Clinic”
Xilio Taps Former Tesaro Exec Martin Huber as Chief Medical Officer
Xilio Therapeutics has appointed Martin Huber to serve as its chief medical officer, the same position he held at Tesaro before its 2018 acquisition by GlaxoSmithKline (NYSE: [[ticker:GSK]]). His experience also includes roles at Merck (NYSE: [[ticker:MRK]]), Schering-Plough, Roche, and Rhone-Poulenc Rorer. Waltham, MA-based Xilio is developing antibody cancer drugs designed to activate their cancer-killing … Continue reading “Xilio Taps Former Tesaro Exec Martin Huber as Chief Medical Officer”
AgenTus VP Mark Exley Appointed Chief Scientific Officer of Imvax
Imvax announced that Mark Exley has joined the biotech as its chief scientific officer. Exley comes to Philadelphia-based Imvax from AgenTus Therapeutics, where he was vice president of cellular immunology. His experience also includes faculty positions at Harvard Medical School and the University of Manchester. Imvax’s lead candidate, a tumor cell vaccine called IGV-001, is … Continue reading “AgenTus VP Mark Exley Appointed Chief Scientific Officer of Imvax”
ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans
Last fall, ADC Therapeutics (ADCT) concluded the time just wasn’t right for an IPO. Six months later, with its lead drug in a pivotal test and plans being drawn up for a regulatory submission and potential commercialization, the cancer drug developer has determined it needs cash now. ADCT refiled its IPO plans late Friday. The … Continue reading “ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans”
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
COVID-19’s spread has clamped down on a lot of economic activity, including the work of developing and testing new medicines. But the FDA isn’t showing signs of slowing down, at least when it comes to drugs filed for accelerated approval. The regulator signed off on three such drugs in the past week. These approvals are … Continue reading “Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More”
Drug Review Times Not Shortened Much by Single Expedited Review Designation
Expedited programs usually shorten a US Food and Drug Administration new drug application assessment, but on average, maybe not as much as their reputation would suggest. A Government Accountability Office (GAO) analysis found that expedited assessment programs generally are significant variables affecting assessment times, but less so than perhaps stakeholders might expect. When all else is equal, … Continue reading “Drug Review Times Not Shortened Much by Single Expedited Review Designation”
ORIC Pharma Gets $120M in IPO to Advance Drug-Resistant Cancer Therapies
ORIC Pharmaceuticals followed in the footsteps of the other biotechs that have managed to go public this month, selling more shares than it expected for a haul of $120 million. The South San Francisco, CA-based company—whose name is an acronym for “overcoming resistance in cancer”—priced its IPO late Thursday, offering 7.5 million shares at $16 … Continue reading “ORIC Pharma Gets $120M in IPO to Advance Drug-Resistant Cancer Therapies”
Nitrome Bio Bags $38M to Prep Parkinson’s Program for the Clinic
Nitrome Biosciences is looking to leverage its research into a class of enzymes involved in the aggregation of a protein characteristic of Parkinson’s disease into a treatment for that and other age-related diseases. This week the San Francisco-based startup raised $38 million, a Series A financing that it anticipates will allow it to ready its … Continue reading “Nitrome Bio Bags $38M to Prep Parkinson’s Program for the Clinic”
American Diabetes Association’s Ratner Joins Virta as Chief Medical Officer
Virta Health has appointed Robert Ratner to serve as its chief medical officer. He was most recently the chief scientific & medical officer for the American Diabetes Association. Ratner is also a professor of medicine at Georgetown University Medical School. San Francisco-based Virta has developed software for diabetes patients that provides nutrition information, counseling, and … Continue reading “American Diabetes Association’s Ratner Joins Virta as Chief Medical Officer”
Ex-Bristol Myers Exec Guyer to Join BioMarin, Succeeding Baffi
BioMarin Pharmaceutical (NASDAQ: [[ticker:BMRN]]) has appointed C. Greg Guyer to serve as its chief technical officer and executive vice president of global manufacturing and technical operations. He is scheduled to start on May 4. Guyer was most recently senior vice president of operations at Bristol Myers Squibb (NYSE: [[ticker:BMY]]). At San Rafael, CA-based BioMarin, he will … Continue reading “Ex-Bristol Myers Exec Guyer to Join BioMarin, Succeeding Baffi”
Affinivax Lands $120M to Take MAPS Tech Into New Vaccine Territory
Affinivax has a lead program with early clinical data showing the potential to best a pharmaceutical giant’s blockbuster vaccine. The startup now has $120 million in financing to see just how much further its technology can go. The Series B round of funding announced Thursday was led by Viking Global Investors. Cambridge, MA-based Affinivax develops … Continue reading “Affinivax Lands $120M to Take MAPS Tech Into New Vaccine Territory”
Life Science a VC Bright Spot in Q1, But Startups May Soon Struggle
Even as the novel coronavirus has derailed daily life and business operations, the life sciences sector continues to see companies make public debuts and ink both financing and partnership deals. In venture capital, US deal activity in the first quarter tallied 2,300 financings totaling $34.2 billion, according to the latest report by the National Venture … Continue reading “Life Science a VC Bright Spot in Q1, But Startups May Soon Struggle”
Biogen Pushes Finalized Filing for Alzheimer’s Drug to Third Quarter
Biogen last year said it would ask the FDA to review its potential Alzheimer’s disease treatment, aducanamab, sometime in “early” 2020. The submission is being made under a rolling review, in which sections of an application are filed as they are completed rather than all at once. Now the Cambridge, MA-based company says the regulatory … Continue reading “Biogen Pushes Finalized Filing for Alzheimer’s Drug to Third Quarter”
Immunomedics Triple Negative Breast Cancer Drug Wins Early FDA Nod
An Immunomedics therapy for an aggressive form of breast cancer won FDA approval on Wednesday. It’s the company’s first regulatory nod, and it covers a product expected to become a blockbuster seller. Morris Plains, NJ-based Immunomedics (NASDAQ: [[ticker:IMMU]]) developed the drug, sacituzumab govitecan (Trodelvy), as a treatment for treat triple negative breast cancer. This form … Continue reading “Immunomedics Triple Negative Breast Cancer Drug Wins Early FDA Nod”
Synthorx’s Shawver Joins Silverback Therapeutics as New Top Exec
Veteran biotech executive Laura Shawver is taking over as CEO at Silverback Therapeutics, joining the cancer drug developer as it is poised to move its first compound into the clinic. The Wednesday announcement comes three months after French firm Sanofi (NYSE: [[ticker:SNY]]) closed its $2.5 billion acquisition of La Jolla, CA-based Synthorx, the biotech Shawver … Continue reading “Synthorx’s Shawver Joins Silverback Therapeutics as New Top Exec”